Ratings CompuGroup Medical Societas Europaea Xetra

Equities

COP

DE0005437305

Delayed Xetra Other stock markets 11:19:08 2021-10-05 am EDT			5-day change	1st Jan Change
69.35 ^EUR	+1.31%		-7.31%	-12.91%

Apr. 25	COMPUGROUP MEDICAL : Jefferies gives a Neutral rating	ZD
Apr. 18	COMPUGROUP MEDICAL : Gets a Buy rating from Deutsche Bank	ZD

Strengths

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.

Weaknesses

The company is in debt and has limited leeway for investment
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last few months, analysts have been revising downwards their earnings forecast.
Over the past four months, analysts' average price target has been revised downwards significantly.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Software

	1st Jan change	Capi.	ESG Refinitiv
COMPUGROUP MEDICAL SOCIETAS EUROPAEA	-12.91%	1.62B	-
ORACLE CORPORATION	+8.97%	317B	B-
SAP SE	+22.02%	218B	B+
CONSTELLATION SOFTWARE INC.	+11.25%	57.09B	D+
HUBSPOT, INC.	+9.57%	33.03B	B+
FAIR ISAAC CORPORATION	+2.55%	29.65B	C+
MICROSTRATEGY INCORPORATED	+96.39%	22.32B	D+
WISETECH GLOBAL LIMITED	+21.52%	19.66B	B-
SAGE GROUP PLC	-1.02%	14.55B	B-
TRIMBLE, INC.	+11.30%	14.53B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes